anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To offer the silver and zinc carrying antibacterial hydroxyapatite which shows safely strong antibacterial power for a long period, heightens a whiteness, and does not cause a change of color by saving it for a long period by allowing hydroxyapatite to absorb and hold water soluble metallic salt of silver and zinc, and thereafter, calcining it. CONSTITUTION:A prescribed quantity of hydroxyapatite is added into a water solution obtained by melting a prescribed quantity of water soluble silver salt and zinc salt, and stirred. After it is stirred enough, a sediment is filtered, washed enough with distilled water, dried, and thereafter, calcined at a prescribed temperature, and thereafter, crushed and target antibacterial hydroxyapatite is obtained. Also, at the time of manufacturing the hydroxypatite by calcium salt and phosphate, water soluble silver salt and zinc salt are allowed to coexist, and thereafter, an obtained sediment is filtered, washed enough with distilled water, dried, and thereafter, calcined by which it is also possible to obtain the hydroxyapatite. The foregoing is desired. As for the zinc quantity allowed to coexist with silver and held, it is necessary that its quantity is at least >=5% by weight against the silver quantity to be held. Also, by executing the calcination at >=961 deg.C being a melting point of silver, the whiteness of powder is further improved.
Asthma is a disease of heterogeneous pathology, typically characterised by excessive inflammatory and bronchoconstrictor responses to the environment. The clinical expression of the disease is a consequence of the interaction between environmental factors and host factors over time, including genetic susceptibility, immune dysregulation and airway remodelling. As a critical interface between the host and the environment, the airway epithelium plays an important role in maintaining homeostasis in the face of environmental challenges. Disruption of epithelial integrity is a key factor contributing to multiple processes underlying asthma pathology. In this review, we first discuss the unmet need in asthma management and provide an overview of the structure and function of the airway epithelium. We then focus on key pathophysiological changes that occur in the airway epithelium, including epithelial barrier disruption, immune hyperreactivity, remodelling, mucus hypersecretion and mucus plugging, highlighting how these processes manifest clinically and how they might be targeted by current and novel therapeutics.
The invention comprises mercapto-pyridazine-2-oxides of the formula <FORM:0997400/C2/1> wherein R is hydrogen or an alkali-metal atom, e.g. potassium, and R1 is an alkyl or aryl group, e.g. methyl or phenyl and their preparation by reacting a 3-halogeno-6-alkoxy- or aryloxypyridazine-2-oxide with an alkali-metal hydrogen sulphide RSH to give an alkali-metal compound of the above formula and, if desired, treating with an acid to give the free compound wherein R is hydrogen. ALSO:Pharmaceutical preparations having an antibiotic effect against micro-organisms comprise compounds of the formula <FORM:0997400/A5-A6/1> wherein R is hydrogen or an alkali-metal atom, e.g. potassium and R1 is an alkyl or aryl group, e.g. methyl or phenyl, in association with a pharmaceutical vehicle for human or veterinary use.  The preparations may suitably take the form of dusting powders, lotions, salves, creams, embrocations and balms for topical use, which when they contain water may also contain a surface-active agent; or the active compounds may be incorporated in toilet preparations such as hair creams, shampoos, liquid and solid soap preparations, cold creams and shaving creams.
INTRODUCTION: Medication-related ear canal osteonecrosis (MRECO) is a growing concern linked to prolonged anti-resorptive medication use. Despite primary care providers being key prescribers of these medications, there is limited information about MRECO in primary care literature. This article presents a case of bisphosphonate-induced osteonecrosis of the external auditory canal (EAC), emphasizing the vital role of primary care providers in identifying this rare yet significant side effect of anti-resorptive medication.
MAIN SYMPTOMS AND CLINICAL FINDINGS: A 65-year-old female, on long-term alendronic acid for osteoporosis, presented to primary care with a 2-year history of left-sided ear blockage and itchiness. Despite prolonged topical treatment for ear wax, symptoms persisted, leading to an Otolaryngology referral. Microsuction revealed exposed bone in the left EAC.
DIAGNOSES, INTERVENTIONS, AND OUTCOMES: A computed tomography scan confirmed bony erosion of the left EAC, and in the absence of other osteonecrosis risk factors, bisphosphonate-induced osteonecrosis was diagnosed. Management involved bisphosphonate discontinuation, regular aural toilet, and topical treatment, achieving complete ear canal epithelialisation within 6 months.
CONCLUSION: MRECO, a rare complication of anti-resorptive therapy, is anticipated to rise with increasing antiresorptive medication use in the ageing population. Unexplained ear symptoms in those with a history of current or prior anti-resorptive therapy should raise clinical concern, prompting evaluation for exposed bone in the EAC. Raising awareness of MRECO among primary care providers is crucial for early diagnosis and timely management.
The present disclosure generally relates to systems and methods for delivering humanin and/or other peptides to a subject. In some cases, these may be used for treating or preventing aging skin, or for other diseases. Non-limiting examples of other peptides include mitochondrial-derived peptides such as HNG or MOTS-c. In addition, certain embodiments are generally directed to treatments that can be delivered using topical compositions applied to the skin. For example, in some cases, the composition includes lecithin and/or other components that may facilitate delivery through the skin. Further, certain embodiments may include active ingredients such as tributyrin or 2,6-dimethyl-L-tyrosine, which may interact with humanin or other peptides. Compositions such as these may be used in certain embodiments, for example, to reduce inflammation within the skin, or as an anti-aging treatment, etc. Other aspects are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely pediatrics, endocrinology. A method involves hypocaloric diet, physiotherapeutic exercises, physiobalneotherapy, drug-induced therapy. It requires diet No.5 with fasting days 2 times a week of calorage 1200-1500 kcal/day. Physiotherapeutic exercises are made daily before noon for 20-30 minutes, 21-24 days. Charcot's douche is taken at pressure 1.5-2 atm, water temperature 36C and covers posterior thighs, buttocks, anterior abdominal wall clockwise for 1-1.5 minutes each. Total exposure duration is 5-7 minutes. The procedure is conducted before noon, daily; a therapeutic course is 10 - 12 procedures. Electrical sleep is induced with using an orbital-occipital technique, at frequency 10-20 Hz, current intensity up to 2 mA for 30-40 minutes. Further, it is possible to allow the patient sleeping with the apparatus off. The procedure is conducted in the afternoon, every second day; a therapeutic course is 10 procedures. Group and individual psychologist consultations are kept for 45-60 minutes, 21-24 days. Corthexin 10 mg is injected intramuscularly daily, course No. 10. ^ EFFECT: method provides higher clinical effectiveness ensured by corrected metabolic, hormonal and vegetative disorders in children, and combined use of Cortexin and preformed physical factors. ^ 2 ex, 8 tbl
The invention relates to a capsule for tonifying qi and blood and restoring yang, wherein the capsule content is a powdery composition prepared by mixing the following medicinal materials in parts by weight: ginseng, astragalus root, eucommia bark, prepared fleece flower root, wolfberry fruit and cortex moutan. On the basis, the medicinal ingredients such as parasitic loranthus, epimedium herb, Szechuan lovage rhizome, prepared rehmannia root, largetrifoliolious bugbane rhizome, Chinese angelica, pilose asiabell root, siberian solomonseal rhizome and the like can be added to prepare targeted second to fourth formulas. The medicines are respectively processed to remove toxin, ground into fine powder, uniformly mixed according to the corresponding proportion and filled into capsules to obtain the traditional Chinese medicine preparation. The capsule is administered with warm water 4-5 granules each time twice a day, and children are allowed to take the capsule with reduced dose or following the medical advice. The invention has the effects of invigorating qi and blood, restoring yang qi, restoring pulse, consolidating constitution, promoting blood circulation, promoting qi circulation, lifting yang qi, tranquilizing mind, improving intelligence, replenishing essence, nourishing marrow, warming kidney, replenishing essence, invigorating spleen, calming heart, consolidating superficial resistance, arresting sweating, activating stagnancy, relieving arthralgia, dispelling blood stasis, eliminating dampness, stimulating appetite, nourishing yin, promoting fluid production, tonifying lung, nourishing heart, inducing diuresis, removing toxic substances, etc. Is a good medicine for treating weak chronic diseases, building up body, promoting blood circulation and softening joints, and can prevent and treat diseases and improve sleep.
Trauma is the leading cause of death in young adults and a major cause of morbidity and mortality at all ages. The acute problem is often uncontrollable bleeding. Subsequently, infection becomes a leading cause of morbidity. Polytrauma patients are at high risk for accidental hypothermia. Mild perioperative hypothermia causes a coagulopathy that significantly augments blood loss and increases allogeneic transfusion requirements. Hypothermia also impairs numerous immune functions - even slight decreases in core temperature triple the risk of surgical wound infection.

Endovascular temperature management system Alsius® (ICY, Alsius Corporation: Irvine,California,USA) has been approved in Europe and United States for the past 10 years and has been used in thousands of patients mainly for the indication of therapeutic cooling and subsequently rewarming of patients. A major potential advantage of this system is that heat is directly added to the thermal core, thus bypassing the heat sink and insulating effects of peripheral tissues. The efficacy of this system is sufficient to allow rapid rewarming in hypothermic trauma victims, even those undergoing major surgery. We therefore propose to test the hypothesis that polytrauma patients rewarmed with the Alsius® system will have better patient outcome (combined perioperative morbidity) than those warmed conventionally with forced-air.
Insulin resistance occurs when blood glucose levels get too high for the body to respond. Certain anti-HIV drugs are associated with increased insulin resistance and may lead to abnormal fat distribution, hypertension, and type 2 diabetes mellitus. The dietary supplement chromium picolinate has been shown to safely improve insulin sensitivity in patients with type 2 diabetes mellitus with no serious side effects. However, the effects of the supplement have not been thoroughly examined in HIV-infected individuals. This study will determine the effectiveness of chromium picolinate in improving insulin resistance in HIV-infected individuals.

This study will last 2 months. Participants will be randomly assigned to receive either chromium picolinate or placebo once a day for 2 months. Participants will have four overnight visits at the research center and two additional daytime visits for safety monitoring. During the overnight visits, participants will undergo a euglycemic hyperinsulinemic clamp, in which a continuous infusion of insulin is given through a vein and glucose levels are monitored through blood samples taken every 5 to 10 minutes. Fat tissue biopsies will also be conducted at the overnight study visits. During the safety monitoring visits, blood collection will occur for kidney and liver function tests, CD4 count, and viral load assessment.
The investigators plan to conduct a clinic-based interventional study of 50 patients followed at Miriam Hospital Kidney Stone Clinic with history of nephrolithiasis, urinary calcium excretion between 150 and 400 mg/day, and 25-vitamin D deficiency/insufficiency (defined as serum level ≤ 30ng/ml). The intervention is oral ergocalciferol 50,000 IU per week for 12 weeks (repletion course). After that, the same repletion course will be repeated if serum 25-vitamin D remains ≤ 30ng/ml or drops to ≤ 30ng/ml anytime during the study. Otherwise, a maintenance dose of cholecalciferol 1,000 IU daily or ergocalciferol 50,000 IU monthly will be prescribed for the rest of the study. Each participant will serve as his own control. The outcome is the change in urinary calcium excretion and stone burden assessed by renal ultrasound. The planned study duration is 12 months. The investigators will have greater than 95% power to detect a 10% increase in 24-hour urinary calcium.
The renin-angiotensin system (RAS) is a complex homeostatic entity with multiorgan systemic and local effects. Traditionally, RAS works in conjunction with the kidney to control effective arterial circulation, systemic vascular resistance, and electrolyte balance. However, chronic hepatic injury and resulting splanchnic dilation may disrupt this delicate balance. The role of RAS in liver disease, however, is even more extensive, modulating hepatic fibrosis and portal hypertension. Recognition of an alternative RAS pathway in the past few decades has changed our understanding of RAS in liver disease, and the concept of opposing vs. "rebalanced" forces is an ongoing focus of research. Whether RAS inhibition is beneficial in patients with chronic liver disease appears to be context-dependent, but further study is needed to optimize clinical management and reduce organ-specific morbidity and mortality. This review presents the current understanding of RAS in liver disease, acknowledges areas of uncertainty, and describes potential areas of future investigation.
The present invention generally relates to a combination therapy of a PARP-inhibitor and olanzapine. More particularly, embodiments relate to a method of administering to a patient one or more of a PARP-inhibitor in a therapeutic amount to a patient in need thereof, and olanzapine, in a sufficient amount to treat or alleviate PARP-inhibitor induced nausea or vomiting. In embodiments, the PARP-inhibitor and olanzapine are administered in a common administration schedule. In some embodiments, both actives are orally administered. In other embodiments, olanzapine is transdermally administered. In certain embodiments, the PARP-inhibitor is one or more of olaparib, rucaparib, and niraparib.
Patients will receive exemestane 25 mg orally per day for 8 weeks. Starting in the 9th week, patients will receive celecoxib 400 mg orally twice per day for 8 weeks in addition to exemestane.
INTRODUCTION: Prostate cancer (PCa) is the most common non-cutaneous tumor among American men. Androgen receptor signaling inhibitors such as abiraterone and enzalutamide have been approved for similar disease states among patients with advanced PCa. Existing data suggest using steroids is associated with an increased risk of infection. Because abiraterone is usually prescribed with prednisone, we sought to compare the risk of septicemia in patients using abiraterone vs. enzalutamide.
MATERIALS AND METHODS: We utilized the SEER-Medicare-linked data and used negative binomial regression models to compare the changes in the rates of septicemia-related hospitalizations six months pre- and post-abiraterone and enzalutamide initiation.
RESULTS: We found that the incidence of septicemia-related hospitalizations increased 2.77 fold within six months of initiating abiraterone (incidence rate ratio [IRR]: 2.77, 95% confidence interval [CI]: 2.17-3.53) 1.97 fold within six months of starting enzalutamide (IRR: 1.97, 95% CI: 1.43-2.72). However, the difference in the changes did not reach statistical significance (interaction IRR: 0.71, 95% CI: 0.48-1.06).
DISCUSSION: The findings suggest that both abiraterone and enzalutamide are associated with an increased risk of septicemia-related hospitalizations. However, the difference in the increase of septicemia risk following the two treatments did not reach statistical significance. Further studies are warranted to understand the mechanisms at play.
Avocado sunblotch viroid (ASBVd) is the type species of the family Avsunviroidae and the causal agent of avocado sunblotch disease. The disease is characterised by the presence of chlorotic lesions on avocado fruit, leaves and/or stems. Infected trees may remain without chlorosis for extended periods of time, though distorted growth and reduced yield has been observed in these cases. The molecular effects of ASBVd on avocado, and members of the Avsunviroidae on their respective hosts in general, remain poorly understood. Host global transcriptomic studies within the family Pospiviroidae have identified several host pathways that are affected during these plant-pathogen interactions. In this study, we used RNA sequencing to investigate host gene expression in asymptomatic avocado nursery trees infected with ASBVd. Transcriptome data showed that 631 genes were differentially expressed, 63 % of which were upregulated during infection. Plant defence responses, phytohormone networks, gene expression pathways, secondary metabolism, cellular transport as well as protein modification and degradation were all significantly affected by ASBVd infection. This work represents the first global gene expression study of ASBVd-infected avocado, and the transcriptional reprogramming observed during this asymptomatic infection improves our understanding of the molecular interactions underlying broader avsunviroid-host interactions.
Researchers have recently found that N6-methyladenosine (m6A) is a type of internal posttranscriptional modification that is essential in mammalian mRNA. However, the features of m6A RNA methylation in acute intracerebral hemorrhage (ICH) remain unknown. To explore differential methylations and to discover their functions in acute ICH patients, we recruited three acute ICH patients, three healthy controls, and an additional three patients and healthy controls for validation. The m6A methylation levels in blood samples from the two groups were determined by ultrahigh-performance liquid chromatography coupled with triple quadruple mass spectrometry (UPLC-QQQ-MS). Methylated RNA immunoprecipitation sequencing (MeRIP-seq) was employed to identify differences in m6A modification, and the differentially expressed m6A-modified genes were confirmed by MeRIP-qPCR. We found no significant differences in the total m6A levels between the two groups but observed differential methylation peaks. Compared with the control group, the coding genes showing increased methylation following acute ICH were mostly involved in processes connected with osteoclast differentiation, the neurotrophin signaling pathway, and the spliceosome, whereas genes with reduced m6A modification levels after acute ICH were found to be involved in the B-cell and T-cell receptor signaling pathways. These results reveal that differentially m6A-modified genes may influence the immune microenvironments in acute ICH.
Purpose: To determine whether performing resistance exercise in hypoxia acutely reduces performance and increases markers of fatigue, and whether these responses are exaggerated if exercising at high versus low work rates (i.e., exercising to failure or volume matched non-failure). Methods: Following a within-subject design, 20 men completed two trials in hypoxia (13% oxygen) and two in normoxia (21% oxygen). The first session for hypoxic and normoxic conditions comprised six sets of bench press and shoulder press to failure (high work rate), while subsequent sessions involved the same volume distributed over 12 sets (low work rate). Physical performance (concentric velocity) and perceptual responses were measured during exercise and for 72 hr post-exercise. Neuromuscular performance (bench throw velocity) was assessed pre- and post-session. Results: Hypoxia did not affect physical performance, neuromuscular performance, and perceptual recovery when exercising at high or low work rates. Higher work rate exercise caused greater acute decrements in physical performance and post-exercise neuromuscular performance and increased perceived exertion and muscle soreness (p ≤ 0.006), irrespective of hypoxia. Conclusions: Hypoxia does not impact on resistance exercise performance or increase markers of physical and perceptual fatigue. Higher exercise work rates may impair physical performance, and exaggerate fatigue compared to low work rate exercise, irrespective of environmental condition. Practitioners can prescribe hypoxic resistance exercise without compromising physical performance or inducing greater levels of fatigue. For athletes who are required to train with high frequency, decreasing exercise work rate may reduce post-exercise markers of fatigue for the same training volume.
Patients will undergo standard of care mapping study with 99TC-MAA to plan for Y90 radioembolization therapy. Additionally,non-standard of care, intervention will be to do a second mapping study using SIR-spheres microspheres with low-dose Y90 (15 mCi) before the therapeutic Y90 radioembolization.
Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.

Ixazomib induced apoptosis of multiple myeloma cell lines in vitro. Ixazomib demonstrated in vitro cytotoxicity against myeloma cells from patients who had relapsed after multiple prior therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide demonstrated synergistic cytotoxic effects in multiple myeloma cell lines. In vivo, ixazomib demonstrated antitumor activity in a mouse multiple myeloma tumor xenograft model.